Value of Thyroid Stimulating Antibody in the Diagnosis of Thyroid Associated Ophthalmopathy of Euthyroid Patients

Overview

Journal Br J Ophthalmol

Specialty Ophthalmology

Date 1998 Mar 14

PMID 9497469

Citations 9

Authors

K Kazuo

T Fujikado

G Ohmi

J Hosohata

Y Tano

Affiliations

Soon will be listed here.

Abstract

Aims/background: Thyroid associated ophthalmopathy (TAO) of euthyroid patients is difficult to diagnose because clinical findings overlap with other conditions, and no confirmatory diagnostic tests are available. Recently, it was reported that TSH binding inhibitor immunoglobulin (TBII) and thyroid stimulating antibody (TSAb) are sensitive markers of TAO. The sensitivity of these antibodies in the detection of TAO were therefore studied to determine if they could be a useful criterion in the diagnosis of TAO of euthyroid patients.

Methods: Serum values of TBII and TSAb of 35 patients with euthyroid TAO (group A) were compared with those of 27 patients with Graves' disease and TAO (group B). The relation between the serum value of TSAb and the eye symptoms of patients with euthyroid TAO were also examined by multiple linear regression analysis.

Results: In group A, TBII was positive in 10 cases (28.6%) and TSAb was positive in 29 cases (82.9%). In group B, both TBII and TSAb were positive in all cases (100%). The titre of serum TBII in group A (15.6% (SD 18.0%)) was significantly lower (p < 0.0001) than in group B (57.9% (21.5%)). The titre of serum TSAb in group A (1400.9% (2163.9%)) was significantly lower (p = 0.0026) than in group B (2243.9% (1472.8%)). Among the eye findings of patients with euthyroid TAO, keratopathy was significantly (p = 0.034) related to the value of TSAb.

Conclusion: These results suggest that the activity of TSAb is a more sensitive marker of euthyroid TAO than is TBII, and could be a useful criterion in the diagnosis of TAO of euthyroid patients.

Citing Articles

Molecular Biomarkers in Thyroid Eye Disease: A Literature Review.

Ueland H, Neset M, Methlie P, Ueland G, Pakdel F, Rodahl E Ophthalmic Plast Reconstr Surg. 2023; 39(6S):S19-S28.

PMID: 38054982 PMC: 10697285. DOI: 10.1097/IOP.0000000000002466.

Usefulness of TSH receptor antibodies as biomarkers for Graves' ophthalmopathy: a systematic review.

Seo S, Sanchez Robledo M J Endocrinol Invest. 2018; 41(12):1457-1468.

PMID: 30194634 DOI: 10.1007/s40618-018-0945-6.

A Case of Euthyroid Graves' Ophthalmopathy in a Patient Sero-Negative for TSH Receptor Autoantibody.

Hotta A, Tanaka T, Kato H, Kakoi S, Shimizu Y, Hasegawa C Case Rep Endocrinol. 2018; 2018:1707959.

PMID: 30009061 PMC: 6020486. DOI: 10.1155/2018/1707959.

Clinical course of thyroid function and thyroid associated-ophthalmopathy in patients with euthyroid Graves' disease.

Suzuki N, Yoshimura Noh J, Kameda T, Yoshihara A, Ohye H, Suzuki M Clin Ophthalmol. 2018; 12:739-746.

PMID: 29719374 PMC: 5914550. DOI: 10.2147/OPTH.S158967.

Thyroid-associated orbitopathy in patients with thyroid carcinoma: A case report of 5 cases.

Yu P, Liu S, Zhou X, Huang T, Li Y, Wang H Medicine (Baltimore). 2018; 96(47):e8768.

PMID: 29381976 PMC: 5708975. DOI: 10.1097/MD.0000000000008768.

References

Biro J . Thyroid-stimulating antibodies in Grave's disease and the effect of thyrotrophin-binding globulins on their determination. J Endocrinol. 1982; 92(2):175-84. DOI: 10.1677/joe.0.0920175. View

Macchia E, Fenzi G, Monzani F, Lippi F, Vitti P, Grasso L . Comparison between thyroid stimulating and tsh-binding inhibiting immunoglobulins of Graves' disease. Clin Endocrinol (Oxf). 1981; 15(2):175-82. DOI: 10.1111/j.1365-2265.1981.tb00652.x. View

Amino N, Yuasa T, Yabu Y, Miyai K, KUMAHARA Y . Exophthalmos in autoimmune thyroid disease. J Clin Endocrinol Metab. 1980; 51(6):1232-4. DOI: 10.1210/jcem-51-6-1232. View

Ambesi-Impiombato F, Parks L, Coon H . Culture of hormone-dependent functional epithelial cells from rat thyroids. Proc Natl Acad Sci U S A. 1980; 77(6):3455-9. PMC: 349635. DOI: 10.1073/pnas.77.6.3455. View

Sugenoya A, Kidd A, Row V, Volpe R . Correlation between thyrotropin-displacing activity and human thyroid-stimulating activity by immunoglobulins from patients with Graves' disease and other thyroid disorders. J Clin Endocrinol Metab. 1979; 48(3):398-402. DOI: 10.1210/jcem-48-3-398. View

WERNER S . Modification of the classification of the eye changes of Graves' disease: recommendations of the Ad Hoc Committee of the American Thyroid Association. J Clin Endocrinol Metab. 1977; 44(1):203-4. DOI: 10.1210/jcem-44-1-203. View

LIDDLE G, HEYSSEL R, McKenzie J . Graves' disease without hyperthyroidism. Am J Med. 1965; 39(5):845-8. DOI: 10.1016/0002-9343(65)90104-x. View

Shewring G, Smith B . An improved radioreceptor assay for TSH receptor antibodies. Clin Endocrinol (Oxf). 1982; 17(4):409-17. DOI: 10.1111/j.1365-2265.1982.tb01607.x. View

Southgate K, Creagh F, Teece M, Kingswood C, Rees Smith B . A receptor assay for the measurement of TSH receptor antibodies in unextracted serum. Clin Endocrinol (Oxf). 1984; 20(5):539-48. DOI: 10.1111/j.1365-2265.1984.tb00102.x. View

10.

Tamaki H, Amino N, Aozasa M, Mori M, TANIZAWA O, Miyai K . Serial changes in thyroid-stimulating antibody and thyrotropin binding inhibitor immunoglobulin at the time of postpartum occurrence of thyrotoxicosis in Graves' disease. J Clin Endocrinol Metab. 1987; 65(2):324-30. DOI: 10.1210/jcem-65-2-324. View

11.

Kasagi K, Hatabu H, Tokuda Y, Arai K, Iida Y, Konishi J . Comparison of thyroid stimulating activities measured by cyclic AMP production, those by radioiodine uptake in FRTL-5 cells and TSH-binding inhibitory activities in patients with hyperthyroid and euthyroid Graves' diseases. Acta Endocrinol (Copenh). 1988; 117(3):365-72. DOI: 10.1530/acta.0.1170365. View

12.

Kasagi K, Hatabu H, Tokuda Y, Iida Y, Endo K, Konishi J . Studies on thyrotrophin receptor antibodies in patients with euthyroid Graves' disease. Clin Endocrinol (Oxf). 1988; 29(4):357-66. DOI: 10.1111/j.1365-2265.1988.tb02884.x. View

13.

Tamaki H, Amino N, Iwatani Y, Miyai K . Improvement of infiltrative ophthalmopathy in parallel with decrease of thyroid-stimulating antibody (TSAb) activity in two patients with hypothyroid Graves' disease. J Endocrinol Invest. 1989; 12(1):47-53. DOI: 10.1007/BF03349918. View

14.

Salvi M, Zhang Z, Haegert D, Woo M, Liberman A, Cadarso L . Patients with endocrine ophthalmopathy not associated with overt thyroid disease have multiple thyroid immunological abnormalities. J Clin Endocrinol Metab. 1990; 70(1):89-94. DOI: 10.1210/jcem-70-1-89. View

15.

Kosugi S, Inoue D, Sugawa H, Enomoto T, Mori T, Imura H . Similarity and dissimilarity between clinical and laboratory findings, especially anti-thyrotropin receptor antibody in ophthalmic Graves' disease without persistent hyperthyroidism and hyperthyroid Graves' disease. Endocrinol Jpn. 1990; 37(3):343-54. DOI: 10.1507/endocrj1954.37.343. View

16.

McLachlan S, BAHN R, Rapoport B . Endocrine ophthalmopathy: a re-evaluation of the association with thyroid autoantibodies. Autoimmunity. 1992; 14(2):143-8. DOI: 10.3109/08916939209083133. View

17.

Feliciello A, Porcellini A, Ciullo I, Bonavolonta G, Avvedimento E, Fenzi G . Expression of thyrotropin-receptor mRNA in healthy and Graves' disease retro-orbital tissue. Lancet. 1993; 342(8867):337-8. DOI: 10.1016/0140-6736(93)91475-2. View

18.

Perros P, Kendall-Taylor P . Demonstration of thyrotropin binding sites in orbital connective tissue: possible role in the pathogenesis of thyroid-associated ophthalmopathy. J Endocrinol Invest. 1994; 17(3):163-70. DOI: 10.1007/BF03347708. View

19.

Perros P, Kendall-Taylor P . Thyroid-associated ophthalmopathy: pathogenesis and clinical management. Baillieres Clin Endocrinol Metab. 1995; 9(1):115-35. DOI: 10.1016/s0950-351x(95)80867-1. View

20.

Ludgate M, Vassart G . The thyrotropin receptor as a model to illustrate receptor and receptor antibody diseases. Baillieres Clin Endocrinol Metab. 1995; 9(1):95-113. DOI: 10.1016/s0950-351x(95)80851-5. View